Jim Simons Provention Bio, Inc. Transaction History

Renaissance Technologies LLC

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	BUY	$6.7 - $24.21 $275,370 - $995,031	41,100 New	41,100 $991,000
Q3 2022 Nov 14, 2022	SELL	$3.43 - $5.62 $464,511 - $761,094	-135,426 Reduced 81.22%	31,321 $141,000
Q2 2022 Aug 12, 2022	BUY	$3.65 - $7.3 $608,626 - $1.22 Million	166,747 New	166,747 $667,000
Q3 2021 Nov 12, 2021	SELL	$5.66 - $8.33 $369,598 - $543,949	-65,300 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$6.71 - $11.04 $1.1 Million - $1.81 Million	-164,100 Reduced 71.53%	65,300 $550,000
Q1 2021 May 13, 2021	BUY	$10.12 - $19.45 $2.32 Million - $4.46 Million	229,400 New	229,400 $2.41 Million
Q2 2020 Aug 13, 2020	SELL	$7.81 - $17.0 $584,156 - $1.27 Million	-74,796 Closed	0 $0
Q1 2020 May 14, 2020	BUY	$5.42 - $17.75 $405,394 - $1.33 Million	74,796 New	74,796 $688,000
Q3 2019 Nov 13, 2019	SELL	$6.83 - $13.0 $106,548 - $202,800	-15,600 Closed	0 $0
Q2 2019 Aug 12, 2019	BUY	$2.3 - $13.79 $35,880 - $215,124	15,600 New	15,600 $189,000

170K

Ticker PRVB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 81,549,904
Description
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one...

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.